Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
American ginseng berry extract (AGBE) is a botanical extract derived from the fruit of *Panax quinquefolius*. It is characterized by a high concentration of ginsenosides, which are the primary active components responsible for its biological activities. Research indicates that AGBE possesses chemopreventive properties, particularly in colorectal cancer, where it has been shown to inhibit cell proliferation and induce cell cycle arrest in the G2/M phase. When used in combination with chemotherapy agents like 5-fluorouracil (5-FU), AGBE may exhibit synergistic effects by enhancing S-phase arrest and potentially reducing the required dose and associated toxicity of the chemotherapy. Unlike the more common root extract, the berry extract contains a distinct profile of ginsenosides, such as ginsenoside Re, which contributes to its unique pharmacological profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on american ginseng berry extract.